Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Synergistic Dual-Receptor Activation Combined stimulation of GHRH and GHS-R1a receptors leads to amplified and sustained GH release, mimicking natural physiologic pulsatility more effectively than monotherapy
Across the wider market as of April 2026, combined monthly totals commonly run from roughly $200 to $700 or more depending on plan and medication
Tirzepatide acts as a dual agonist (GLP-1 + GIP), while semaglutide is a single GLP-1 agonist
The propensity scores were modeled using a machine learning method called eXtreme Gradient Boosting (XGBoost), which uses a decision tree ensemble approach to optimize the balance of baseline covariates utilized for matching
This results in: Systemic muscle growth across the entire body Enhanced fat metabolism and insulin sensitivity Ideal pairing with long-acting growth agents like HGH, MK-677, and anabolic steroids Long R3 IGF-1 was engineered to increase receptor activity and reduce IGFBP interference, extending its biological availability and enhancing systemic effects. Duan, Frontiers in Endocrinology IGF-1 DES (1-3): Targeted Anabolic Precision IGF-1 DES is a truncated analog that removes the first three amino acids from the IGF-1 protein chain
